CCL2 and non-small cell lung carcinoma: Indeed, we have previously reported that tumor-derived microvesicles (TMVs) from non-small-cell lung cancer (NSCLC) cells can activate MCs to release several mediators, including TNF-α and monocyte chemoattractant protein 1 (MCP-1)/ CC chemokine ligand 2 (CCL2), as well as enhancing both their chemotactic and chemokinetic activity [12].